These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32779954)

  • 1. Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients.
    Minakuchi H; Yoshida T; Kaburagi N; Fujino T; Endo S; Takemitsu TY; Yamashita N; Itoh H; Oya M
    Ren Fail; 2020 Nov; 42(1):799-806. PubMed ID: 32779954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
    Yoshida T; Morimoto K; Kaburagi N; Fujino T; Takemitsu TY; Yamashita N; Oya M
    Int Urol Nephrol; 2022 Apr; 54(4):861-872. PubMed ID: 34264473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
    Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
    BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.
    Yaguchi A; Akahane K; Tsuchioka K; Yonekubo S; Yamamoto S; Tamai Y; Tatemichi S; Takeda H
    BMC Nephrol; 2019 Dec; 20(1):465. PubMed ID: 31830936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
    Isaka Y; Hamano T; Fujii H; Tsujimoto Y; Koiwa F; Sakaguchi Y; Tanaka R; Tomiyama N; Tatsugami F; Teramukai S
    J Am Soc Nephrol; 2021 Mar; 32(3):723-735. PubMed ID: 33547218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL; Plosker GL
    Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
    Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
    Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
    Schmid H; Lederer SR
    Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
    Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate binders in chronic kidney disease: a systematic review of recent data.
    Floege J
    J Nephrol; 2016 Jun; 29(3):329-340. PubMed ID: 26800972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
    Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
    J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Floege J
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.
    Sprague SM; Ketteler M; Covic AC; Floege J; Rakov V; Walpen S; Rastogi A
    Hemodial Int; 2018 Oct; 22(4):480-491. PubMed ID: 29656600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A; Al-Makki A; Sutton J; Shepler B
    Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
    Sprague SM; Covic AC; Floege J; Ketteler M; Botha J; Chong EM; Rastogi A
    Am J Nephrol; 2016; 44(2):104-12. PubMed ID: 27434393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J
    J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.
    Otsuki T; Utsunomiya K; Moriuchi M; Horikoshi S; Okamura M; Suzuki H; Okamura M; Maruyama N; Shibahara N; Abe M
    Nephron; 2018; 140(3):161-168. PubMed ID: 29991053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.